<DOC>
	<DOCNO>NCT00466726</DOCNO>
	<brief_summary>RATIONALE : Vaccines make peptide may help body build effective immune response kill cancer cell . Colony-stimulating factor , GM-CSF , may increase number immune cell find bone marrow peripheral blood . Giving booster vaccination may make strong immune response prevent delay recurrence cancer . PURPOSE : This phase II trial study well vaccine therapy work treat patient Philadelphia chromosome-positive chronic myelogenous leukemia .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine activity bcr-abl p210-b3a2 breakpoint-derived pentapeptide vaccine ( CMLVAX100 ) , term peripheral blood bcr-abl/abl ratio reduction , patient Philadelphia chromosome-positive chronic myelogenous leukemia . Secondary - Determine reduction molecular residual disease 3 month patient treat vaccine . - Determine reduction molecular residual disease 12 month patient treat maintenance boost vaccine . - Determine rate complete molecular response time vaccination . - Determine vivo vitro peptide-specific immune response induce vaccine . OUTLINE : This prospective , nonrandomized , open-label , multicenter study . Patients receive sargramostim ( GM-CSF ) subcutaneously ( SC ) day 1 2 bcr-abl p210-b3a2 breakpoint-derived pentapeptide vaccine ( CMLVAX100 ) SC day 2 . Treatment repeat every 2 week 6 course . Patients receive CMLVAX100 SC monthly 3 month every 3 month 6 month ( total 1 year ) . Patients may receive additional CMLVAX100 SC every 6 month least 3 year . Treatment continue absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 69 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic myelogenous leukemia ( CML ) meeting follow criterion : Philadelphia chromosome positive disease b3a2 breakpoint mutation Prior treatment conventional imatinib mesylate ≥ 18 month require Complete cytogenetic response document ≥ 2 different examination Persistence molecularly detectable residual disease ( level bcrabl transcript ) Patients continue receive imatinib mesylate dose ( conventional treatment ) study treatment PATIENT CHARACTERISTICS : WHO performance status 01 Bilirubin ≤ 2 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Creatinine ≤ 1.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No severe active infection serious medical illness would preclude study completion No known immunodeficiency No autoimmune disorder PRIOR CONCURRENT THERAPY : No concurrent immunosuppression systemic immunosuppressive medication No concurrent dose escalation imatinib mesylate No concurrent investigational product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
</DOC>